Efficacy of Portal Vein Embolization with a Procedure of Sheath Injection and Balloon Occlusion with Gelatin Sponge

Introduction

Portal vein embolization (PVE) is an established presurgical procedure intended to increase the volume and function of the future liver remnant (FLR) prior to hepatic resection and thereby decrease the risk of associated morbidity and mortality [1, 2]. Many reports have described the efficacy and safety of PVE using various institution-dependent PVE techniques and embolic materials, such as absolute ethanol, n-butyl-2-cyanoacrylate (NBCA), ethanolamine oleate (EOI), coil, polyvinyl alcohol (PVA), and gelatin sponge (GS) [3]. Nevertheless, these methods and materials have their limitations. One approach often used to perform PVE involves a reverse-curve catheter technique, but this method may be time-consuming according to portal vein anatomy and it is sometimes difficult to obtain the required shape. Similarly, a nonabsorbable agent is commonly used to carry out permanent vascular occlusion [4], but a temporary embolization agent is often used because it’s easy to use [5]. Performed prior to hepatectomy, PVE should be as simple and safe as possible. Accordingly, our protocol has been to inject GS via a gap of sheath and straight catheter under proximal balloon occlusion (PVE-SIBO). We believe few reports describe the use, safety, efficacy, and associated complications of this method; therefore, we undertook a retrospective evaluation of these considerations in our patients.

Materials and Methods

Our institutional review board approved this retrospective study and waived the requirement for patients’ informed consent for the use of their data for this study.

PVE-SIBO procedure

After local anaesthesia, a percutaneous transhepatic approach to the right portal vein branch was performed. A 6- to 8-French sheath (MEDIKIT catheter introducer; Togo Medikit, Tokyo, Japan) was inserted, a balloon catheter (Selecon MP catheter II, 9- to 20-mm diameter; Terumo Clinical Supply, Gifu, Japan; Moiyan 5-Fr, 9-mm balloon; Tokai Medical Products, Inc., Aichi, Japan; or Occlusion catheter, 5-Fr, 20-mm balloon; Nipro, Osaka, Japan) was inflated to occlude the proximal region of the right portal vein, and a mixture of one sheet of 1-mm square sized gelatin sponge (GELFOAM™, Pfizer, Tokyo, Japan) pieces and 10-ml of contrast agent was injected into the vein through the gap between the sheath and the balloon catheter (Figure 1). Portography was performed to confirm occlusion of the vein via the balloon catheter (Figures 2 and 3). Fibered coils (Tornado, 3 mm × 5 cm, COOK Medical, Tokyo, Japan) were used to embolize the PVE tract, and the sheath was removed.

Figure 1

Figure 2

Figure 3

Results

PVE-SIBO was performed successfully in all 20 cases, with complete obstruction of the right portal vein as confirmed on digital subtraction portography at the end of the procedure. GS was the only embolization agent used. The mean amount of GS sheets and contrast media required per one session were 5.87 ± 3.98 sheets and 58.7 ± 39.8 ml, respectively. Though the mixture of GS used in our study was slightly viscous, it was smoothly injected through the gap between the sheath and catheter in the PVE-SIBO procedure. Sheath size varied from 6- to 8-French depending on the type of balloon catheter, but this caused no difficulty in injection. Procedure time for all but Cases 1 and 2, for which information was insufficient, was 52.7 ± 11.4 minutes.

CT scanning performed after a mean of 14.3 ± 2.57 days after PVE did not show any PVE-related complications above Grade 3, including subcapsular hematoma, intra-abdominal bleeding, or bile leakage. Table 2 allows comparison of the FLR volumes before and after initial PVE. The FLR volume increased from 413.5 ± 133.0 mL to 556.3 ± 190.1 mL. The increased ratio of FLR volume was 34.7 ± 23.7% and there was a significant difference in the FLR volume before and after initial PVE (P < 0.01).

Recanalization was confirmed in five patients, two of whom (Cases 2 and 8) required additional PVE because of the insufficient FLR/TLV ratio after initial PVE (20.1% and 28.3%, respectively). The additional PVE were performed within 4 weeks after the first: a second time PVE-SIBO with GS and transileocolic PVE with GS in Cases 2 and 8, respectively, and the FLR volume increased sufficiently. FLR increase ratios after the additional PVE were 17.9% and 58.6%.

The clinical outcomes are shown in Table 2. Extended right hepatectomy or right hepatectomy were performed in 14 of the 20 patients after PVE-SIBO with GS. Three hepatic resections in Cases 3, 7, and 10 were cancelled because of peritoneal metastasis detected during the operation. The fourteen patients who had hepatectomy did not develop hepatic failure.

Treatments in Cases 11 and 13 were altered from surgery to chemotherapy due to progression of tumour invasion after PVE. Radiation therapy, not hepatic resection, was performed on the patient’s request in Case 16 after PVE.

Discussion

Our retrospective study demonstrated a greater technical ease of PVE-SIBO with GS than those reported using other techniques and embolic agents to achieve an acceptable increase in FLR/TLV ratio prior to hepatic resection. Our procedure was simpler because it required no extra manipulations, such as in the reverse-curve catheter technique and cannulation to each branch of right portal vein. Few studies have discussed the operative time for PVE, which were defined with shorter ranges compared to ours [8]. Even though the average procedure time of 52.7 ± 11.4 minutes in this study can be clinically acceptable, it was not clear if PVE-SIBO with GS was superior to other techniques with respect to time because of lack of a common definition for procedure time.

Tsurusaki’s team achieved an adequate increase in FLR/TLV ratio utilizing the same method of PVE-SIBO, but they used absolute ethanol, a pure liquid, as their embolization agent [9]. Although easily injected through the gap between the sheath and catheter, absolute alcohol can induce strong hepatic inflammation after embolization that may cause adhesions that interfere with operational manipulation during hepatectomy [10, 11]. Absolute ethanol, PVA and NBCA are nonabsorbable agents and reported to be effective in increasing the FLR/TLV ratio in PVE, but their use requires great skill and has a risk of non-target embolization [8, 9, 12, 13, 14]. The use of GS could be safer in cases of accidental contralateral embolization and in clinical situations in which the liver is not ultimately resected secondary to concomitant tumour progression after PVE. The cost of GS is lower than that of PVA or NBCA. Moreover, NBCA is not a suitable agent for PVE-SBIO technique due to the risk of adherence to the sheath and catheter. Although it is not covered by our national insurance system, ethylene vinyl alcohol may be a suitable non-adhesive embolic agent for PVE-SIBO.

We could achieve an increased ratio of FLR volume of 34.7 ± 23.7% using PVE-SIBO with GS. Tranchart and colleagues reported a slightly less increased FLR ratio (29.4 ± 6.9%) than ours using PVE with only GS [4], but this may be attributable to their not employing balloon occlusion, which was useful to fill the portal vein with a larger amount of GS. Other reports describe the performance of PVE using GS mixed with other embolic agents, including increase in FLR ratio of 30.7 ± 25.6% for PVE using GS mixed with coils and 30.0 ± 21.0% for PVE with GS mixed with EOI foam [15, 16]. These procedures were more complex than ours and yielded inferior increase in FLR ratio compared to that of PVE-SIBO with GS alone.

The reported incidence of major complications, such as subcapsular hematoma, bile leakage, and non-targeted portal vein thrombosis after PVE, is 0–9% in the literature [12], but we observed no obvious complications, possibly because of the simplicity of our procedure.

Although we observed a relatively higher recanalization rate, 25.0%, than that reported by others, we consider this as acceptable because only two patients, 10.0% of our total cases, required additional embolization and were finally able to undergo hepatectomy. Furthermore, we observed a comparable recanalization rate to that of other reports of PVE with GS [4, 14]. Recently, Berggren et al. reported almost an equivalent recanalization rate of 26.0% using PVE with NBCA [8].

All 14 patients who had hepatectomy did not develop hepatic failure. Although further investigation and accumulation of cases for PVE-SIBO are required, this hepatic failure rate after hepatectomy might be comparable to PVE with GS (1.50%), PVA or NBCA (4.0–10.0%) [8, 17, 18, 19].

Our study was limited by its retrospective design, conducted in a single centre, and absence of randomization and comparison with other embolic agents. Further prospective, multi-institutional, randomized, larger patient population investigation utilizing PVE-SIBO with GS is required.

Conclusion

We found percutaneous transhepatic PVE-SIBO with GS a safe and simple procedure with comparable efficacy to that of other previously reported techniques to increase the FLR volume prior to hepatic resection.

Competing Interests

The authors have no competing interests to declare.